Family Medicine
M-A | Utility of the Ages and Stages Questionnaire to identify developmental delay in children aged 12 to 60 months.
30 Aug, 2022 | 12:00h | UTCUtility of the Ages and Stages Questionnaire to Identify Developmental Delay in Children Aged 12 to 60 Months: A Systematic Review and Meta-analysis – JAMA Pediatrics (free for a limited period)
Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.
30 Aug, 2022 | 11:59h | UTCAcute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)
M-A | Midodrine for the prevention of vasovagal syncope.
30 Aug, 2022 | 11:56h | UTCRelated: RCT: Midodrine can reduce the recurrence of vasovagal syncope.
Cohort Study | Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis.
30 Aug, 2022 | 11:53h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1562922771730305030
Study shows an increasing incidence of hypertensive disorders in pregnancy.
30 Aug, 2022 | 11:52h | UTCCommentaries:
Increased incidence of hypertensive disorders of pregnancy in young Americans – News Medical
Hypertensive Disorders in Pregnancy on the Rise – AJMC
Commentary on Twitter
Independent birth cohort effect on rates of hypertensive disorders of pregnancy higher incidence in younger generations and persistent racial and ethnic disparities. Increased awareness even among young pregnant people is needed. #OAResearch https://t.co/wNwIZTYLHZ
— JAMA Network Open (@JAMANetworkOpen) August 24, 2022
#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.
29 Aug, 2022 | 12:38h | UTCPercutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology
Commentary on Twitter
REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
#ESCCongress – RCT | Routine functional testing is not better than standard care in high-risk patients after percutaneous coronary intervention.
29 Aug, 2022 | 12:32h | UTCRoutine Functional Testing or Standard Care in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
POST-PCI: In a randomized trial of patients who underwent percutaneous coronary intervention, routine stress testing did not improve clinical outcomes at two years. #ESCCongress https://t.co/nil00HQm4Z pic.twitter.com/o4v0UcDfYV
— NEJM (@NEJM) August 28, 2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
#ESCCongress | 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.
29 Aug, 2022 | 12:22h | UTCNews Release: All patients over 65 years should have a heart check before high-risk non-cardiac surgery – European Society of Cardiology
#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.
29 Aug, 2022 | 12:24h | UTCFive-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology
Commentary on Twitter
DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK
— NEJM (@NEJM) August 27, 2022
#ESCCongress | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
29 Aug, 2022 | 12:18h | UTCNews Release: Pulmonary hypertension guidelines call for earlier diagnosis – European Society of Cardiology
[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.
29 Aug, 2022 | 12:15h | UTCCommentary:
ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD
No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now
Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
29 Aug, 2022 | 12:11h | UTCAutoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)
Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress
M-A | Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum.
29 Aug, 2022 | 12:06h | UTC
Prevalence of multiple non-communicable diseases risk factors among adolescents in 140 countries: a population-based study.
29 Aug, 2022 | 12:04h | UTC
Commentary on Twitter
Our study shows that a large proportion of adolescents in all countries are exposed to four or more NCD risk factors, irrespective of region. Insufficient vegetable and fruit consumption, sedentary behaviour and physical inactivity were most prevalent. https://t.co/NKz2VXTiYG pic.twitter.com/E0fM7h7fRz
— M Mamun Huda (@mmamunhuda) August 13, 2022
Meta-analysis of randomized trials | Intensive vs. short face-to-face smoking cessation interventions.
29 Aug, 2022 | 12:03h | UTC
Network Meta-Analysis | Antithrombotic therapy for symptomatic peripheral arterial disease.
26 Aug, 2022 | 13:28h | UTC
RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.
26 Aug, 2022 | 13:29h | UTCEffectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco
Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist
Commentary on Twitter
Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC
— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022
RCT | HPV self-sampling among long-term non-attenders to cervical cancer screening.
26 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Pragmatic randomised controlled trial of 3 different HPV screening approaches suggests that opt-in and particularlly send-to-all self-sampling increased participation among long-term, higher-risk non-attenders: https://t.co/hBouqoBMnU #GynCSM #hsronc
— NatureRevClinOncol (@NatRevClinOncol) August 25, 2022
Secondary analysis of a RCT | Effects of Empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.
26 Aug, 2022 | 13:24h | UTCCommentary: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay
Original Study: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine